GV1001治疗良性前列腺增生的随机安慰剂对照2期临床试验
这项随机、安慰剂对照、多中心2期试验评估了GV1001三种给药方案在良性前列腺增生(BPH)患者中的疗效与安全性。共纳入161例患者,主要终点为IPSS总分自基线的变化。结果显示GV1001组1和组2在第13周IPSS改善显著优于对照组,且所有治疗组前列腺体积在第16周显著缩小,不良事件与安慰剂相似。
要点
- GV1001 0.4mg和0.56mg每2周方案可显著改善BPH患者IPSS。
- 所有GV1001治疗组均显著缩小前列腺体积。
- GV1001安全性与安慰剂相似,未见药物相关不良事件。
核心结论
- GV1001在BPH患者中有效且耐受性良好,可能提供潜在获益。
- 与需每日给药的药物相比,GV1001的便捷给药方案可能提高患者依从性。
研究设计与样本
- 随机、安慰剂对照、多中心2期临床试验。
- 纳入161例≥50岁男性BPH患者,随机分为4组:组1 GV1001 0.4mg每2周、组2 0.56mg每2周、组3 0.56mg每4周、组4安慰剂。
- 治疗12周,共7次皮内注射,疗效评估至第16周。
主要发现
- 第13周时,组1和组2的IPSS平均变化分别为-7.2和-6.8,对照组为-3.5,差异有统计学意义(均P<0.05)。
- 符合方案人群中,组1和组2在第8、12、13、16周的IPSS变化与对照组差异有统计学意义。
- 第16周时,所有治疗组前列腺体积较对照组显著缩小:对照组0.8mL,组1 -4.6mL、组2 -2.5mL、组3 -4.2mL(均P<0.05)。
- 其他次要终点(Qmax、PVR、IIEF、睾酮、DHT、PSA)未见统计学显著差异。
- 不良事件报告在四组间相似,无治疗中出现的不良事件被认为与研究药物相关。
关键数值与推荐
- 纳入标准:年龄≥50岁,IPSS≥13,Qmax 5-15 mL/s,PVR≤200 mL,前列腺体积≥30 mL。
- 主要疗效变量:IPSS总分自基线变化(CFB)。
- 给药方案:组1 0.4mg每2周;组2 0.56mg每2周;组3 0.56mg每4周;共7次注射。
临床怎么用
- GV1001每2周给药方案可能作为BPH的潜在治疗选择,尤其适用于偏好低频给药的患者。
- 治疗期间需监测IPSS和前列腺体积变化以评估疗效。
局限性
- 样本量较小(161例),需大规模临床评估进一步验证。
- 随访时间较短(16周),长期疗效和安全性未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the efficacy and safety of three dosing schemes of GV1001 in patients with benign prostatic hyperplasia (BPH). PATIENTS AND METHODS: Eligible patients were men aged ≥50 years, with an International Prostate Symptom Score (IPSS) of ≥13, maximum urinary flow rate (Qmax ) of 5-15 mL/s, post-void residual urine volume (PVR) of ≤200 mL, and prostate volume of ≥30 mL. After a 4 week run-in period, patients were randomly assigned to one of three treatment schedules: Group 1, GV1001 0.4 mg, 2-week interval; Group 2, GV1001 0.56 mg, 2-week interval; Group 3, GV1001 0.56 mg, 4-week interval) or placebo (Group 4). The eligible patients were administered GV1001 or placebo, for a total of seven intradermal injections that were administered at 2-week intervals at weeks 0, 2, 4, 6, 8, 10, and 12. Treatment continued for 12 weeks, and efficacy was evaluated at weeks 4, 8, 12, 13, and 16. Safety was evaluated throughout the 16-week period. The primary efficacy variable was change from baseline (CFB) in total IPSS. Secondary endpoints were CFB in Qmax , PVR, prostate volume, International Index of Erectile Function score, plasma testosterone level, dihydrotestosterone level, and prostate-specific antigen level. RESULTS: A total of 161 patients were included (Group 1, n = 41; Groups 2-4, n = 40). Most patients (88.8%) received all planned doses of the study treatment. At week 13, a statistically significant difference in the mean CFB in IPSS was seen in GV1001 treatment Groups 1 and 2 vs the control group for the full analysis population (-3.5 [control] vs -7.2 and -6.8 in Groups 1 and 2, respectively; both P < 0.05). There were also statistically significant differences in CFB at weeks 8, 12, 13, and 16 in treatment Groups 1 and 2 vs control in the per-protocol population. There was a statistically significant reduction in prostate gland volume at week 16 vs control in all treatment groups (0.8 [control] vs -4.6, -2.5, and -4.2 mL in Groups 1-3, respectively; all P < 0.05). There were no statistically significant differences found in other secondary outcome measures. Adverse event (AE) reporting was similar across all four groups. No treatment-emergent AEs were considered to be related to the study drug. CONCLUSIONS: The results indicate that GV1001 was effective and well tolerated, and may provide potential beneficial effects in patients with BPH. Compared with medical therapies that require daily dosing, the convenient dosing regimen of GV1001 may provide greater patient adherence. Further investigation of these observations will require large-scale clinical evaluation.
引用
- Moon KT, Yoo TK, Kwon SY, et al. A randomised, placebo-controlled, multicentre, Phase 2 clinical trial to evaluate the efficacy and safety of GV1001 in patients with benign prostatic hyperplasia. BJU Int. 2018. PMID: 29633507. doi:10.1111/bju.14233
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。